Comparison between standard dose and high dose of filgrastim for neutrophil recovery after cytarabine consolidation chemotherapy in acute myeloid leukemia patients.
Not Applicable
Recruiting
- Conditions
- The Patient aged 18 years and overand Non-M3 acute myeloid leukemia patients in the sedative stage who received cytarabine consolidation therapyComparison between standard dose and high dose of filgrastim for neutrophil recovery after cytarabine consolidation chemotherapy in acute myeloid leukemia patients.
- Registration Number
- TCTR20201010001
- Lead Sponsor
- Siriraj Hospital Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Non-M3 acute myeloid leukemia patients in the sedative stage who received cytarabine consolidation therapy
2. CBC had absolute neutrophil count> 1,000 / μL and platelet count ≥ 100,000 / μL and blast cell <5% in bone. marrow
3. Patient aged 18 years and over.
Exclusion Criteria
1. Patients with other types of cancer or an infection that has spread into the bone marrow
2. Patients receiving immunosuppressants who also treat other diseases.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of leukocytes in patients acute myeloid leukemia receiving filgrastim 2 years Number in leukocytes patients per normal population
- Secondary Outcome Measures
Name Time Method Reduce infection and side effects 2 yaers Number in infection and side effects patients in normal